A TREATMENT that involves genetically modifying the body's immune cells has been found to cut the risk of disease progression by 74 percent in people with a rare type of blood cancer, results showed Monday (Tuesday in Manila).
Ciltacabtagene autoleucel — also known by its trade name Carvykti — was tested in a clinical trial involving 419 patients with multiple myeloma, whose disease was not responsive to the current frontline drug lenalidomide, a chemotherapy medicine.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.